Karuna Therapeutics is a clinical-stage biopharmaceutical company that focuses on transformative medicines for people living with psychiatric and neurological conditions. Co.'s proprietary product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. Co. is developing KarXT for the treatment of psychosis in adults with schizophrenia as well as for the treatment of psychosis in Alzheimer's disease.
KRTX — Key Stats (updated Friday, September 23, 10:35 AM)